Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

Stock Information for Akari Therapeutics Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akari Therapeutics Plc

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger - SDPI, MINM, SCX, AKTX
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm
INVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK
Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.